Silverarc Capital Management, LLC Uni Qure N.V. Transaction History

Silverarc Capital Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $181,200 - $273,200	10,000 New	10,000 $226,000
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $243,089 - $357,204	-9,346 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.97 - $37.17 $280,099 - $347,390	9,346 New	9,346 $288,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.